Literature DB >> 8871884

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection.

J Main1, J L Brown, C Howells, R Galassini, M Crossey, P Karayiannis, P Georgiou, G Atkinson, H C Thomas.   

Abstract

This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carries. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8871884     DOI： 10.1111/j.1365-2893.1996.tb00098.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN： 1352-0504            Impact factor:   3.728


  12 in total

1.  In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.

Authors:  D Colledge; G Civitico; S Locarnini; T Shaw
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 2.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.

Authors:  L Stuyver; C Van Geyt; S De Gendt; G Van Reybroeck; F Zoulim; G Leroux-Roels; R Rossau
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 5.  Mitochondrial injury. Lessons from the fialuridine trial.

Authors:  P Honkoop; H R Scholte; R A de Man; S W Schalm
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

6.  Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.

Authors:  S W Aberle; J Kletzmayr; B Watschinger; B Schmied; N Vetter; E Puchhammer-Stöckl
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

Review 7.  Recent advances in antiviral therapy.

Authors:  D Kinchington
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 8.  Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV.

Authors:  K Deres; H Rübsamen-Waigmann
Journal:  Infection       Date:  1999       Impact factor: 3.553

9.  Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Authors:  A J Nicoll; D L Colledge; J J Toole; P W Angus; R A Smallwood; S A Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; D Colledge; Y Y Wang; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.